|Bid||340.77 x 4000|
|Ask||340.24 x 1000|
|Day's range||338.45 - 341.67|
|52-week range||275.89 - 475.35|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||38.01|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||0.72 (0.21%)|
|Ex-dividend date||19 Jul 2022|
|1y target est||383.17|
This morning, Eric Green and Bernard Birkett will review our financial results, provide an update on our business and present an update on our financial outlook for the remaining full year of 2022. There is a slide presentation that accompanies today's call and a copy of that presentation is available on the Investors section of our website.
West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.
West Pharmaceutical (WST) delivered earnings and revenue surprises of 12.79% and 2.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?